ArticleJournal of the American Chemical Society2018
Supramolecularly Engineered Circular Bivalent Aptamer for Enhanced Functional Protein Delivery.
Article in Journal of the American Chemical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 112 citations in OpenAlex.
- Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- CAR19-T/NK cell and circular aptamer-drug conjugate (ApDC) combination treatment increases immunotherapy efficacy.Molecular and cellular biochemistry · 2025Article
- Serum assisted PD-L1 aptamer screening for improving its stability.Scientific reports · 2025Article
- Aptamer based immunotherapy: a potential solid tumor therapeutic.Frontiers in immunology · 2025Review
- Review
- Evolution of a bispecific G-quadruplex-forming circular aptamer to block IL-6/sIL-6R interaction for inflammation inhibition.Chemical science · 2024Article
- Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells.International journal of molecular sciences · 2024Article
- The effect of charge and albumin on cellular uptake of supramolecular polymer nanostructures.Journal of materials chemistry. B · 2024Article
- Single-nucleobase resolution of a surface energy transfer nanoruler forChemical science · 2023Article
- DNA Volume, Topology, and Flexibility Dictate Nanopore Current Signals.Nano letters · 2023Article
- Aptamers 101: aptamer discovery andChemical science · 2023Review
- A versatile strategy for convenient circular bivalent functional nucleic acids construction.National science review · 2023Article
- Optimization of Gonyautoxin1/4-Binding G-Quadruplex Aptamers by Label-Free Surface-Enhanced Raman Spectroscopy.Toxins · 2022Article
- Cancer immunomodulation using bispecific aptamers.Molecular therapy. Nucleic acids · 2022Review
- Single-stranded circular DNA theranostics.Theranostics · 2022Review
- Review
- A bispecific circular aptamer tethering a built-in universal molecular tag for functional protein delivery.Chemical science · 2020Article
- Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics.Advanced pharmaceutical bulletin · 2020Review
- Cytosolic Delivery of Functional ProteinsACS applied materials & interfaces · 2020Article
- Engineering base-excised aptamers for highly specific recognition of adenosine.Chemical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Circular bivalent aptamers (cb-apt) comprise an emerging class of chemically engineered aptamers with substantially improved stability and molecular recognition ability. Its therapeutic application, however, is challenged by the lack of functional modules to control the interactions of cb-apt with therapeutics. We present the design of a β-cyclodextrin-modified cb-apt (cb-apt-βCD) and its supramolecular interaction with molecular therapeutics via host-guest chemistry for targeted intracellular delivery. The supramolecular ensemble exhibits high serum stability and enhanced intracellular delivery efficiency compared to a monomeric aptamer. The cb-apt-βCD ensemble delivers green fluorescent protein into targeted cells with efficiency as high as 80%, or cytotoxic saporin to efficiently inhibit tumor cell growth. The strategy of conjugating βCD to cb-apt, and subsequently modulating the supramolecular chemistry of cb-apt-βCD, provides a general platform to expand and diversify the function of aptamers, enabling new biological and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.